memantine hydrochloride


Also found in: Dictionary.
Related to memantine hydrochloride: donepezil hydrochloride

me·man·tine hydrochloride

(mə-măn′tēn)
n.
A drug used to treat moderate to severe symptoms of Alzheimer's disease, whose action is to inhibit NMDA receptors.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
India-based multinational pharmaceutical firm Zydus Cadila has been granted final approval from the US Food and Drug Administration (FDA) to commercialise Memantine Hydrochloride tablets in the United States, its listed entity Cadila Healthcare (NSE: CADILHC) reported on Wednesday.
To reduce the cost of treating this increasingly prevalent condition in China, the State Food and Drug Administration of China approved clinical trials of a domestically manufactured generic version of memantine hydrochloride (jointly developed by Anhui Huachen Pharmaceutical Ltd and Bio-technology Ltd of the University of Science and Technology of China; approval number 2005L02694).
Pharmaceutical products company Lannett Company (NYSE:LCI) reported on Monday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg for the treatment of moderate to severe dementia.
M2 PHARMA-November 15, 2016-Lannett awarded US FDA approval for Memantine Hydrochloride Tablets USP, 5 mg And 10 mg
Reddy's announced last month its launch of memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of Namenda (memantine HC1) tablets in the United States.
M2 EQUITYBITES-October 15, 2015-Lannett passes US FDA approval for Memantine Hydrochloride Oral Solution, 2 mg/ml to treat dementia associated with Alzheimer's disease
M2 PHARMA-October 15, 2015-Lannett passes US FDA approval for Memantine Hydrochloride Oral Solution, 2 mg/ml to treat dementia associated with Alzheimer's disease
Pharmaceutical company Mylan NV (NasdaqGS:MYL) reported on Tuesday the availability of Memantine Hydrochloride Tablets, USP, 5 mg and 10 mg, in the US market.
Lupin has received the tentative approval for its abbreviated new drug applications for memantine hydrochloride tablets in 5-mg and 10-mg strengths, and been given the nod from the FDA to market perindopril erbumine tablets in strengths of 2 mg, 4 mg and 8 mg.